Manila Times Business
Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026
Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim data from 10 enrolled patientsA manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in several patientsSEONGNAM and SEOUL, South Korea, June 15, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the Phase 1/2a interim clinical results for 'RZ-001 (Taspitimagene
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Cebu gets a bold new beat as Radisson RED makes its Philippine debut
Just now
Manz Asia Successfully Delivers World's First 310mm × 310mm Panel-Level Packaging ECD Production System
Just now
Form 8.3 - [ANIMALCARE GROUP PLC - 12 06 2026] - (CGWL)
Just now
Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 12 06 2026] - (CGWL)
Just now